Supplementary results

TKI intolerance
Considering all treatment lines for analysis, side effects were reported in 177/305 patients treated with imatinib (58%), 58/139 patients treated with nilotinib (42%) and 61/116 patients treated with dasatinib (53%) in any line. Cytopenia (in particular thrombocytopenia), fatigue and infections were reported frequently (>5%) during all three forms of treatment (supplemental table S2). Gastrointestinal complaints (in particular diarrhea) were far more common in patients treated with imatinib and dasatinib, whereas rash was more often observed during imatinib and nilotinib treatment. Imatinib showed high rates of fluid retention (both superficial and periorbital) and musculoskeletal symptoms, while pleural effusion was observed frequently during dasatinib treatment. Lastly, cardiovascular events were observed at a high rate (5.8%) during nilotinib treatment. Actions following the different adverse events are shown in supplemental table S2.
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